In addition, compared to previous meta-analyses, our study incorporated a recently published NATALEE study and observed a notable improvement in IDFS associated with CDK4/6 inhibitors in the treatment of early-stage breast cancer, but previous meta-analyses failed to achieve statistical significance. Here, CDK4 is linked to breast carcinoma.